NetworkNews Audio Announces Audio Press Release (APR) Discussing Overcoming Limitations on First-Generation GLP-1 Drug Therapies

The most recent news release dated May 15, 2026, is an Audio Press Release (APR) distributed via NetworkNews summarizing the company's progress on GEP-44. It reiterates that SureNano Science is advancing a patented next-generation metabolic therapy designed to overcome limitations of first-generation GLP-1 drugs. The release confirms GEP-44 acts as a triple agonist targeting GLP-1 and peptide YY receptors Y1 and Y2, with preclinical studies showing reductions in food intake, body weight, and gastrointestinal side effects like nausea. It notes the compound was developed at Syracuse University and acquired via GlucaPharm Inc. This information mirrors the detailed data released on May 13 and May 12, 2026, regarding the same triple agonist mechanism and preclinical performance metrics (e.g., ~15% weight loss vs liraglutide).

The most recent news release is categorized as Routine - Positive. It does not introduce new material information that would alter the investment thesis established in the preceding days (May 12-13) or months (April-February). The core value driver remains GEP-44, and the May 15 release serves primarily to reinforce existing narrative momentum through media distribution rather than announcing a milestone change (such as a new clinical trial start date beyond IND-enabling studies announced in April, or a new partnership). While positive for sentiment maintenance, it lacks the novelty required for a Material - Positive rating. The market has already priced in the acquisition of GlucaPharm and the initiation of FDA IND-enabling studies.

SureNano Science Ltd. is transitioning from a surfactant distribution business (SureNano™) into a pharmaceutical company focused on metabolic therapies. The flagship asset is GEP-44, a patented triple agonist peptide acquired via GlucaPharm Inc. in February 2026. GEP-44 targets obesity and type 2 diabetes mellitus by acting on GLP-1 and peptide YY receptors Y1/Y2. It is currently in the IND-enabling study phase (toxicology/pharmacology) with plans to submit for Phase I clinical trials in Australia. The company aims to differentiate itself through improved tolerability (reduced nausea) compared to first-generation GLP-1 therapies like liraglutide and potential non-injectable delivery methods (oral, sublingual).